The Latest

The Grant Aims Accelerator Program pairs an early career professional with an experienced mentor to review the mentee’s Specific Aims draft (or international Specific Aims equivalent) for grant proposals. Exclusive to Endocrine Society members, mentors and mentees will be matched by research interests and will meet informally at the ENDO 2026 to discuss how the specific aims draft can be improved. Register for ENDO and sign up by Monday, May 4.

Join us on Tuesday, April 21, at 11:00 AM ET for a joint webinar covering obesity management, weight wellness, and musculoskeletal health. Participate in the online panel discussion of the unmet scientific/clinical needs and future directions. Register now!

Checkpoint inhibitor–associated diabetes (CIADM) is an increasingly recognized immune-related adverse event. Taking place Wednesday, April 29 at 5:00 PM ET, this webinar will review approaches to risk prediction and pre-treatment screening, strategies to distinguish CIADM from other causes of hyperglycemia, and emerging insights into underlying immunologic mechanisms, with a focus on implications for future prevention and patient care.

As we transition to a new warehouse, all orders, including Endocrine Self-Assessment Program (ESAP)™ 2026, books, and merchandise, will ship after May 4. ESAP™ 2026 features 120 new case-based questions that reflect real clinical practice and strengthen clinical judgment. The program includes a book, online learning, and a mobile app. Earn up to 40 AMA PRA Category 1 Credits™ and 40 ABIM MOC credits.

An Apology To Dr. Mary Claire Haver

Host Aaron Lohr talks with Sara R. MacLeod, DO, MPH, of the University of Rochester; and Shannon K. Idzik, DNP, CRNP, ANP-BC, FAANP, FAAN, of the University of Maryland School of Nursing, about the recently established Endocrinology Certificate for Advanced Practice Providers.

Host Chase Hendrickson, MD, MPH, MHCC, from Vanderbilt University, talks with regular contributor Andy Crawford, MD, from Dartmouth-Hitchcock Medical Center, and guest expert Giuseppe Barbesino, MD, from Harvard Medical School in Boston, about the paper "Impact of Minimal Dose Strategy Before Antithyroid Drug Discontinuation on Relapse Risk in Graves' Disease" by Miyamura et al., published in the August 2025 issue of JCEM.